Sitrin Capital Management LLC trimmed its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 1.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 26,431 shares of the medical instruments supplier’s stock after selling 276 shares during the period. Becton Dickinson and makes up approximately 3.6% of Sitrin Capital Management LLC’s investment portfolio, making the stock its 13th largest holding. Sitrin Capital Management LLC’s holdings in Becton Dickinson and were worth $6,661,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. NEXT Financial Group Inc boosted its position in Becton Dickinson and by 21.4% during the 2nd quarter. NEXT Financial Group Inc now owns 578 shares of the medical instruments supplier’s stock worth $145,000 after acquiring an additional 102 shares during the period. Cornerstone Advisors Inc. boosted its position in Becton Dickinson and by 27.1% during the 2nd quarter. Cornerstone Advisors Inc. now owns 726 shares of the medical instruments supplier’s stock worth $183,000 after acquiring an additional 155 shares during the period. Spectrum Asset Management Inc. NB CA acquired a new stake in Becton Dickinson and during the 2nd quarter worth about $1,085,000. City Holding Co. boosted its position in Becton Dickinson and by 2.0% during the 2nd quarter. City Holding Co. now owns 7,424 shares of the medical instruments supplier’s stock worth $1,871,000 after acquiring an additional 145 shares during the period. Finally, Pratt Collard Advisory Partners LLC boosted its position in Becton Dickinson and by 39.0% during the 2nd quarter. Pratt Collard Advisory Partners LLC now owns 2,888 shares of the medical instruments supplier’s stock worth $728,000 after acquiring an additional 810 shares during the period. 84.55% of the stock is currently owned by institutional investors.

Shares of BDX stock opened at $254.39 on Friday. The firm has a 50 day moving average of $247.96. The company has a debt-to-equity ratio of 0.82, a current ratio of 0.96 and a quick ratio of 0.59. Becton Dickinson and Co has a twelve month low of $208.62 and a twelve month high of $265.87. The company has a market cap of $68.62 billion, a P/E ratio of 23.11, a price-to-earnings-growth ratio of 1.88 and a beta of 1.12.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.57 by $0.02. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The business had revenue of $4.20 billion for the quarter, compared to the consensus estimate of $4.25 billion. During the same period last year, the business earned $2.65 EPS. The firm’s revenue was down .6% compared to the same quarter last year. Sell-side analysts predict that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 1.21%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

A number of equities research analysts have commented on the company. Wells Fargo & Co decreased their price objective on Nevro from $75.00 to $70.00 and set an “outperform” rating for the company in a research report on Monday, May 13th. Zacks Investment Research lowered GreenTree Hospitality Group from a “buy” rating to a “hold” rating in a report on Monday, May 20th. Barclays lowered Buckeye Partners from an “overweight” rating to an “equal weight” rating in a report on Monday, May 13th. KeyCorp lifted their price target on Harsco from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Friday, May 10th. Finally, Raymond James set a C$1.00 price target on Orezone Gold and gave the company an “outperform” rating in a report on Friday, June 28th. Five research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $263.58.

In other Becton Dickinson and news, EVP Samrat S. Khichi sold 16,085 shares of Becton Dickinson and stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total value of $3,774,827.80. Following the transaction, the executive vice president now directly owns 12,608 shares of the company’s stock, valued at approximately $2,958,845.44. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Betty D. Larson sold 1,700 shares of Becton Dickinson and stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $224.97, for a total value of $382,449.00. Following the completion of the transaction, the executive vice president now directly owns 11,493 shares in the company, valued at $2,585,580.21. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,154 shares of company stock worth $4,955,775. Company insiders own 0.12% of the company’s stock.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: Call Option Volume

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.